a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:4333:"Jacky Vonderscher, PhD, co-founder and Chief Executive Officer, stated "Our move to our new headquarters will position our team to work in close proximity to Lyon’s medical, biotechnology and higher education communities and its thriving culture of innovation. The Company intends to generate further growth through strategic partnerships. Although pioglitazone is not approved by the FDA for the treatment of NASH, it is the most extensively studied drug for NASH and has demonstrated “resolution of NASH without worsening of fibrosis” in a Phase 4 trial. Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20190919005307/en/, http://www.businesswire.com/news/home/20190919005307/en. The Company expects to report data from this trial in the second half of 2020. afloyer@newcap.fr. EYP001 and the Company’s discovery programs are based on a proprietary technology platform that uses a virus bio-mimetism approach to enable the rapid discovery of first-in-class drug candidates with good safety profiles. Together, with our partner Sumitomo Dainippon Pharma, we have successfully completed the Phase 3 TIMES program for the treatment of type 2 diabetes in Japan. Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). He currently serves as a Managing Director of Danforth Advisors and most recently served as CFO of Histogenics Corporation, a publicly-traded cell therapy company developing products for the orthopedics market. ENYO Pharma also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH). EA Pharma Co., Ltd. Development Pipeline as of Aug, 2020; Therapeutic Area Development Code Imeglimin acts on all three key organs which play an important role in the treatment of type 2 diabetes: the pancreas, muscles, and the liver, and it has demonstrated glucose lowering benefits by increasing insulin secretion in response to glucose, improving insulin sensitivity and suppressing gluconeogenesis. Preclinical studies are underway to assess the combination potential of PXL770 and PXL065 with other agents in development for the treatment of NASH. In our mid-to-late stage pipeline, we are currently advancing three drug candidates as well as earlier-stage opportunities from our AMPK activation and TZD platforms. Based on its central metabolic role, targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as NASH. Annie-Florence Loyer, NewCap Media The Company expects to report data from this trial in H2 2020 (NCT 03812029). EYP001 and the Company’s discovery programs are based on a proprietary technology platform that uses a virus bio-mimetism approach to enable the rapid discovery of first-in-class drug candidates with good safety profiles. communication@enyopharma.com, Media Relations: AMPK is a central regulator of multiple metabolic pathways leading to the control of lipid metabolism, glucose homeostasis and inflammation. Enyo has completed a Phase 1 study and they are currently conducting Phase 2 trials in Hepatitis B and NASH. Our new location will also provide a more integrated space for our teams to more efficiently support our clinical and pre-clinical pipeline.". ‒ New Location to Support Long-term Growth and Advancement of Pipeline ‒. Pioglitazone is a 1:1 mixture of two mirror-image compounds (R- and S-stereoisomers) that interconvert in vivo. LYON, France--(BUSINESS WIRE)--ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company’s headquarters to the 8th Arrondissement in Lyon. Additional Pipeline Opportunities +33 (0)1 44 71 00 12/ +33 (0)6 88 20 35 59 communication@enyopharma.com, Media Relations: http://www.businesswire.com/news/home/20190919005307/en, © 1985 - 2020 BioSpace.com. ENYO Pharma is a privately held, clinical stage biopharmaceutical company incorporated in January 2014 and headquartered in Lyon, France. ";s:7:"keyword";s:20:"enyo pharma pipeline";s:5:"links";s:1222:"Ring Always Home, Nursing T-shirts Breastfeeding, Nuffield Health Gyms, Melbourne Business School Terms, John Middleton Tobacco Tins, Quadruplex For Sale, Sonequa Martin-green Parents, Graduate Diploma Of Professional Engineering Curtin, Tallaght Hospital Blood Test, Matrix Structure Of Nestle, ";s:7:"expired";i:-1;}